Raffaele Califano
@caliraf
Followers
1K
Following
2K
Media
67
Statuses
1K
Thoracic Oncologist @TheChristieNHS, Honorary Professor @UoM_DCS . Member @myesmo Educational Publication WG. Views are my own No DMs or medical advice given.
Manchester, England
Joined March 2011
I am sorry I cannot respond to specific requests for medical advice or DMs.
0
0
1
RT @dplanchard: Thrilled to have a fantastic lung team at #ESMOAcademy25 ! Best of luck to our young oncologists taking the ESMO exams @myE….
0
6
0
RT @DrJNaidoo: #ESMOAcademy25 .Irish trainees 🇮🇪 in full force at the ESMO academy in Prague 🇨🇿 thanks to @myESMO for putting together this….
0
3
0
RT @dplanchard: If you want to know everything about the management of metastatic NSCLC and SCLC, check out the ESMO Academy slides/present….
0
5
0
RT @dplanchard: A year has flown by, and here we go again with ESMO Academy 2025 in Prague! Such a pleasure to be surrounded by my incredib….
0
5
0
RT @RobertoFerrara_: Want to dive into patterns, biomarkers and strategies to overcome primary and acquired resistance to immunotherapy in….
nature.com
Nature Reviews Clinical Oncology - Immune-checkpoint inhibitors have dramatically improved the outcomes in patients with advanced-stage driver-negative non-small-cell lung cancer (NSCLC), although...
0
20
0
We have a trial open for patients with advanced EGFR mutant NSCLC (common mut) whose disease has progressed after osimertinib as a later line of therapy. If interested, please contact the-christie.LungResearchTeam@nhs.net.@BTOGORG @EgfrUk @EGFRResisters @RoyCastle.
0
4
9
We’re recruiting patients in a study using olomorasib in combination with pembrolizumab with/without chemotherapy for 1L treatment of patients with advanced non-small cell lung cancer harbouring a KRAS G12C mut. Contact the-christie.LungResearchTeam@nhs.net @BTOGORG @KRASKickers.
0
4
15
RT @hsbalata: Greater Manchester first area to diagnose more than 1000 people with lung cancer early - About Manchester. #WorldLungCancerDa….
aboutmanchester.co.uk
Greater Manchester has become the first area in England to diagnose more than 1,000 people with lung cancer earlier thanks to innovative NHS Lung Cancer
0
5
0
RT @OncoAlert: Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS Study . .
0
13
0
Do you want to sub-specialise in lung cancer?.Please come and work with me and the Lung Team @TheChristieNHS and apply for an ESO fellowship. Deadline is mid September!. For informal enquiries, please email Linda.scott23@nhs.net.
eso.net
ESO - The Clinical Training Centres Fellowship programme gives oncology professionals the opportunity to spend a period of time at a Centre of Excellence in Europe.
0
7
35
RT @DrJNaidoo: Excited to serve as @myESMO faculty for the #ESMOAcademy 2025 . 📅 22-24 Aug.📍 Prague, Czech Republic . Join us as we review….
0
4
0
RT @dplanchard: It's going to be a great lung session @myESMO, like every year! Happy to share this with @DrJNaidoo @caliraf and our young….
0
3
0
RT @medoncodoc: An extensive review on therapeutic advancements in SCLC. #LCSM . @dplanchard @APassaroMD @BenjaminB….
0
25
0
RT @safwaan_adam: So pleased this is published and represents the hard work put in by our wonderful resident doctors showing their spark fo….
mdpi.com
There is growing evidence relating to the risk of cancer in people with obesity. Obesity is already established as one of the strongest predisposing factors to cancer, and ‘obesity-related’ cancers...
0
1
0
RT @caliraf: @TheChristieNHS is an approved Centre for the ESO fellowship programme. If you are motivated and want to sub specialise in t….
eso.net
ESO - The Clinical Training Centres Fellowship programme gives oncology professionals the opportunity to spend a period of time at a Centre of Excellence in Europe.
0
6
0
RT @StephenVLiu: Proud to be part of the IMforte effort - the first phase 3 maintenance study in #SCLC to show a survival benefit with an O….
thelancet.com
IRF progression-free survival and overall survival were longer in the lurbinectedin plus atezolizumab group than the atezolizumab group for patients with ES-SCLC, albeit with a higher incidence of...
0
23
0
Here is a summary of our findings for the Mariposa 2 trial analysis reported at #ASCO25 @BTOGORG @EgfrUk @EGFRResisters.
ascopost.com
0
2
6